WA-SORACOM
20.7.2022 14:03:48 CEST | Business Wire | Press release
Soracom , Inc., a global provider of advanced IoT connectivity, today announced a partnership with IDEMIA, a leading company in identity technologies, to offer innovative SMBs, SMEs and enterprises in North America and Europe expanded embedded universal integrated circuit card (eUICC) capabilities based on IDEMIA's IoT-optimized DAKOTA SMART eSIM technology. The offering is the first deployment of DAKOTA SMART in the United States.
This GSMA-certified eSIM is designed to specifically meet the needs of IoT devices, even low-cost devices with highly constrained memory, power and processing capability. IDEMIA’s eSIM technology features advanced low-power capabilities, including Suspend, Resume, and eDRX, making it more power efficient for LTE-M/NB-IoT services while supporting all cellular standards from 2G to 5G where available. It is available in standard MFF2 (5x6mm), ultra-compact plug-in card (2x2mm), and chip scale package (CSP) form factors with commercial- and industrial-grade versions available.
The cloud-native Soracom platform is also intended specifically for the needs of the companies and teams building new experiences around connected devices. Soracom's global connectivity and industry-leading network management tools help to reduce total cost of ownership, accelerate speed to market, and ensure complete control over every connection in a customer's IoT fleet.
In addition to the GSMA standard Remote SIM Provisioning capability, DAKOTA SMART is compatible with Soracom's Subscription Containers multi-IMSI solution, which extends profile management capabilities to any Soracom SIM or eSIM connected with Soracom’s standard global data plan. This allows profile-swapping where multiple profiles are available without interrupting access to Soracom platform services.
“Many potential IoT applications have strict requirements in terms of highly constrained memory, power and processing capabilities,” said Kenta Yasukawa, cofounder and CTO at Soracom. “Together, Soracom and IDEMIA are removing these barriers to entry, making it simple for companies to build new, leading-edge IoT experiences for their customers around the world.”
“The ever-evolving world of IoT demands and drives innovation to help bring this connected world to life. We are delighted to be part of the Soracom journey as they expand their global reach and technology evolution. Utilizing our flagship eSIM solution, with its full range of connectivity options, form factors and dedicated IoT features, together we will enable new innovative solutions in this diverse ecosystem,” said Jason Rousseau-Hall, Business Director for IoT M2M, Connectivity Services, IDEMIA.
For more information on opportunities to deploy IDEMIA DAKOTA SMART eSIM solutions on the Soracom platform, visit www.soracom.io .
About IDEMIA
As leader in identity technologies, IDEMIA is on a mission to unlock the world and make it safer. Backed by cutting-edge R&D, IDEMIA provides unique technologies, underpinned by long-standing expertise in biometrics, cryptography, data analytics, systems and smart devices. IDEMIA offers its public and private customers payment, connectivity, access control, travel, identity and public security solutions. Every day, around the world, IDEMIA secures billions of interactions in the physical and digital worlds.
With nearly 15,000 employees, IDEMIA is trusted by over 600 governmental organizations and more than 2,300 enterprises spread over 180 countries, with an impactful, ethical and socially responsible approach.
For more information, visit www.idemia.com and follow @IDEMIAGroup on Twitter.
About Soracom
Soracom is leading the democratization of IoT connectivity, offering robust solutions specifically designed to make it easy to build, operate, and scale IoT deployments. Founded in 2015, Soracom now serves more than 20,000 startups, SMBs and global enterprises across all industries, from agriculture, energy, construction and transportation to consumer electronics, manufacturing, real estate and healthcare. Customers trust Soracom for affordable, reliable connectivity that accelerates speed to market, makes it easy to connect to the cloud, and offers access to a worldwide partner ecosystem. More information is available at www.soracom.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005275/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom